Accordingly, here we show the potential efficacy of pancreatic cancer by CEACAM6-EBET ADC powered by its cancer-cell-killing activity, stromal modulation activity, and good antibody profile. This evidence concerns the gene CEACAM6 and familial pancreatic carcinoma.